共 40 条
- [1] Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (01): : 44
- [2] Correction: Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (04):
- [3] Post Kala-Azar Dermal Leishmaniasis following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) for Primary Visceral Leishmaniasis in Bihar, India [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (01):
- [5] Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients following Treatment with 20 mg/kg Liposomal Amphotericin B (Ambisome) in Bihar, India (vol 8, e2536, 2014) [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (03):
- [6] Five-Year Field Results and Long-Term Effectiveness of 20 mg/kg Liposomal Amphotericin B (Ambisome) for Visceral Leishmaniasis in Bihar, India [J]. PLOS NEGLECTED TROPICAL DISEASES, 2014, 8 (01): : 46
- [9] Combination liposomal amphotericin B (AmBisome®, AmB) and miltefosine (MF) for the treatment of visceral leishmaniasis (VL) in northern Bihar, India [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2007, 77 (05): : 109 - 109
- [10] Effectiveness and Safety of Liposomal Amphotericin B for Visceral Leishmaniasis under Routine Program Conditions in Bihar, India [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2010, 83 (02): : 357 - 364